Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

6-Mercaptopurine (6MP) Intake during Maintenance for Childhood Acute Lymphoblastic Leukemia (ALL) - a Comparison of Self-Report and Electronic Monitoring: A Report from the Children's Oncology Group (COG) Study AALL03N1

Wendy Landier, PhD CRNP, Yanjun Chen, MS, Lindsey Hageman, MPH, Heeyoung Kim, MS, Bruce C. Bostrom, MD, Jacqueline Casillas, MD, M.S.H.S., David Dickens, MD, William E. Evans, PharmD, Kelly W. Maloney, MD, Leo Mascarenhas, MD MS, Arthur K. Ritchey, MD, Amanda M. Termuhlen, MD, William L. Carroll, MD, F. Lennie Wong, Mary V. Relling, PharmD, Smita Bhatia, MD MPH

Blood (2015) 126 (23): 82.

https://doi.org/10.1182/blood.V126.23.82.82

Published: 2015

Journal Articles

Impact of 6 Mercaptopurine (6MP) Pill-Taking Habits on Adherence, Thioguanine Nucleotide (TGN) Levels and Relapse Risk in Children with Acute Lymphoblastic Leukemia (ALL): Results from a Children’s Oncology Group (COG) Study (AALL03N1)

Lindsey Hageman, Wendy Landier, PhD, R.N., Yanjun Chen, MS, Heeyoung Kim, M.S., Nancy Kornegay, M.S., William E. Evans, PharmD, Bruce C. Bostrom, MD, Jacqueline Casillas, MD, M.S.H.S., David Dickens, MD, Anne Angiolillo, MD, Glen Lew, MD, Kelly Maloney, MD, Leo Mascarenhas, Arthur K. Ritchey, MD, Amanda Termuhlen, MD, William L. Carroll, MD, Mary V. Relling, PharmD, F. Lennie Wong, Smita Bhatia, PhD

Blood (2014) 124 (21): 369.

https://doi.org/10.1182/blood.V124.21.369.369

Published: 2014

Journal Articles

A Phase I Dose Finding Study of Panobinostat in Children with Hematologic Malignancies: Initial Report of TACL Study T2009-012 in Children with Acute Leukemia

Blood (2014) 124 (21): 3705.

https://doi.org/10.1182/blood.V124.21.3705.3705

Published: 2014

Journal Articles

High Intra-Individual Variability In Systemic Exposure To 6 Mercaptopurine (6MP) In Children With Acute Lymphoblastic Leukemia (ALL) Contributes To ALL Relapse: Results From a Children’s Oncology Group (COG) Study (AALL03N1)

Smita Bhatia, Ph.D., Wendy Landier, Ph.D., R.N., Lindsey Hageman, Can-Lan Sun, Heeyoung Kim, M.S., Nancy Kornegay, M.S., William E. Evans, PharmD, Bruce C. Bostrom, MD, Jacqueline Casillas, M.D., M.S.H.S, Anne Angiolillo, MD, Glen Lew, MD, Kelly Maloney, MD, Leo Mascarenhas, Jane Meza, Ph.D., A. Kim Ritchey, MD, Amanda Termuhlen, MD, William L. Carroll, MD, F. Lennie Wong, PhD, Mary V. Relling, PharmD

Blood (2013) 122 (21): 59.

https://doi.org/10.1182/blood.V122.21.59.59

Published: 2013

Journal Articles

Nonadherence to Oral 6-Mercaptopurine (6MP) in a Multi-Ethnic Cohort of Children with Acute Lymphoblastic Leukemia (ALL) and Its Impact On Relapse – a Children's Oncology Group (COG) Study (AALL03N1)

Smita Bhatia, MD, MPH, Wendy Landier, Ph.D., R.N., Lindsey Hageman, M.P.H., Heeyoung Kim, M.S., Cara Hanby, B.S., Kornegay Nancy, M.S., Bruce C. Bostrom, MD, Jacqueline Casillas, M.D., M.S.H.S., David S Dickens, M.D., Kelly W. Maloney, MD, Leo Mascarenhas, Jane Meza, Ph.D., Arthur Kim Ritchey, MD, Amanda M Termuhlen, M.D., William L. Carroll, MD, F. Lennie Wong, PhD, Mary V. Relling, PharmD

Blood (2012) 120 (21): 882.

https://doi.org/10.1182/blood.V120.21.882.882

Published: 2012

Journal Articles

Bortezomib Combined with VXLD Chemotherapy Is Highly Effective In Advanced B-Lineage Acute Lymphoblastic Leukemia Allowing Early Study Termination Due to Efficacy. A Therapeutic Advances in Childhood Leukemia (TACL) Consortium Phase II Study

Yoav H Messinger, MD, Paul Gaynon, MD, Richard Sposto, Ph.D., Jeannette van der Giessen, BA, CCRP, Elena Eckroth, CCRC, Jemily Malvar, M.S., Bruce C. Bostrom, MD

Blood (2011) 118 (21): 251.

https://doi.org/10.1182/blood.V118.21.251.251

Published: 2011

Journal Articles

Children with Down Syndrome (DS) and NCI Standard Risk (SR) Acute Lymphoblastic Leukemia (ALL) Have a Superior Five-Year Event-Free Survival (EFS) When Treated with Escalating Intravenous Methotrexate on the Children's Cancer Group (CCG) Study 1991

Yousif Matloub, MD, Bruce C. Bostrom, MD, Stephen Hunger, MD, Anne Angiolillo, MD, Meenakshi Devidas, PhD, Mei La, Nyla A. Heerema, Ph.D., Naomi Winick, MD, James Nachman, MD, Harland Sather, PhD, William L. Carroll, MD, Paul S Gaynon, MD

Blood (2010) 116 (21): 497.

https://doi.org/10.1182/blood.V116.21.497.497

Published: 2010

Journal Articles

Children with NCI Standard Risk Acute Lymphoblastic Leukemia (ALL) and TEL-AML1 or Favorable Chromosome Trisomies Are Almost Certain to Be Cured with Graduated Intensity Therapy: Results of the CCG - 1991 Study.

Yousif Matloub, MD, Bruce C. Bostrom, MD, Anne L Angiolillo, MD, Meenakshi Devidas, PhD, Nyla A. Heerema, PhD, Julie M. Gastier-Foster, PhD, Stephen P Hunger, MD, Harland Sather, PhD, Stephen Linda, William L. Carroll, MD, James B Nachman, MD, Paul S. Gaynon, MD

Blood (2009) 114 (22): 320.

https://doi.org/10.1182/blood.V114.22.320.320

Published: 2009

Journal Articles

Escalating Dose Intravenous Methotrexate without Leucovorin Rescue during Interim Maintenance Is Superior to Oral Methotrexate for Children with Standard Risk Acute Lymphoblastic Leukemia (SR-ALL): Children’s Oncology Group Study 1991

Yousif Matloub, MD, Bruce C. Bostrom, MD, Stephen P. Hunger, MD, Anne L Angiolillo, MD, Catherine Cole, MD, Blythe Thomson, MD, Meenakshi Devidas, PhD, Nyla A. Heerema, PhD, Mei K La, Patrick J. Buckley, MD, PhD, William L. Carroll, MD, Naomi Winick, MD, Harland Sather, PhD, James B Nachman, MD, Paul S. Gaynon, MD

Blood (2008) 112 (11): 9.

https://doi.org/10.1182/blood.V112.11.9.9

Published: 2008

Journal Articles

Bone Marrow (BM) Minimal Residual Disease (MRD) at End of Induction and Interim Maintenance Is Highly Predictive of Outcome in Children with Standard Risk (SR) Acute Lymphoblastic Leukemia (ALL) Treated on the Children’s Oncology Group Study 1991

Yousif Matloub, MD, Paul S. Gaynon, MD, Somasundaram Jayabose, MD, Bruce C. Bostrom, MD, Stephen P. Hunger, MD, Anne L Angiolillo, MD, Meenakshi Devidas, PhD, Stephen Linda, William L. Carroll, MD, Naomi Winick, MD, Harland Sather, PhD, Sharon R Pine, PhD

Blood (2008) 112 (11): 701.

https://doi.org/10.1182/blood.V112.11.701.701

Published: 2008

Journal Articles

Remarkable Activity of Bortezomib Combined with Chemotherapy in a Phase I Study of Relapsed Childhood Acute Lymphoblastic Leukemia (ALL). A Report from the Therapeutic Advances in Childhood Leukemia (TACL) Consortium.

Yoav H. Messinger, MD, Paul S. Gaynon, MD, Elizabeth Raetz, MD, Raymond Hutchinson, MD, MS, Steven DuBois, MD, Julia Glade Bender, MD, Richard Sposto, PhD, Jeannette van der Giessen, BA, CCRP, Elena Eckroth, CCRC, Bruce C. Bostrom, MD

Blood (2008) 112 (11): 1919.

https://doi.org/10.1182/blood.V112.11.1919.1919

Published: 2008

NARROW

6-Mercaptopurine (6MP) Intake during Maintenance for Childhood Acute Lymphoblastic Leukemia (ALL) - a Comparison of Self-Report and Electronic Monitoring: A Report from the Children's Oncology Group (COG) Study AALL03N1

Impact of 6 Mercaptopurine (6MP) Pill-Taking Habits on Adherence, Thioguanine Nucleotide (TGN) Levels and Relapse Risk in Children with Acute Lymphoblastic Leukemia (ALL): Results from a Children’s Oncology Group (COG) Study (AALL03N1)

A Phase I Dose Finding Study of Panobinostat in Children with Hematologic Malignancies: Initial Report of TACL Study T2009-012 in Children with Acute Leukemia

High Intra-Individual Variability In Systemic Exposure To 6 Mercaptopurine (6MP) In Children With Acute Lymphoblastic Leukemia (ALL) Contributes To ALL Relapse: Results From a Children’s Oncology Group (COG) Study (AALL03N1)

Nonadherence to Oral 6-Mercaptopurine (6MP) in a Multi-Ethnic Cohort of Children with Acute Lymphoblastic Leukemia (ALL) and Its Impact On Relapse – a Children's Oncology Group (COG) Study (AALL03N1)

Bortezomib Combined with VXLD Chemotherapy Is Highly Effective In Advanced B-Lineage Acute Lymphoblastic Leukemia Allowing Early Study Termination Due to Efficacy. A Therapeutic Advances in Childhood Leukemia (TACL) Consortium Phase II Study

Children with Down Syndrome (DS) and NCI Standard Risk (SR) Acute Lymphoblastic Leukemia (ALL) Have a Superior Five-Year Event-Free Survival (EFS) When Treated with Escalating Intravenous Methotrexate on the Children's Cancer Group (CCG) Study 1991

Children with NCI Standard Risk Acute Lymphoblastic Leukemia (ALL) and TEL-AML1 or Favorable Chromosome Trisomies Are Almost Certain to Be Cured with Graduated Intensity Therapy: Results of the CCG - 1991 Study.

Escalating Dose Intravenous Methotrexate without Leucovorin Rescue during Interim Maintenance Is Superior to Oral Methotrexate for Children with Standard Risk Acute Lymphoblastic Leukemia (SR-ALL): Children’s Oncology Group Study 1991

Bone Marrow (BM) Minimal Residual Disease (MRD) at End of Induction and Interim Maintenance Is Highly Predictive of Outcome in Children with Standard Risk (SR) Acute Lymphoblastic Leukemia (ALL) Treated on the Children’s Oncology Group Study 1991

Remarkable Activity of Bortezomib Combined with Chemotherapy in a Phase I Study of Relapsed Childhood Acute Lymphoblastic Leukemia (ALL). A Report from the Therapeutic Advances in Childhood Leukemia (TACL) Consortium.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only